Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA.

Charles Herbaux,Olivier Casasnovas,Pierre Feugier,Gandhi Damaj,Reda Bouabdallah,Stéphanie Guidez,Loic Ysebaert,Hervé Tilly,Steven Le Gouill,Luc Fornecker,Nicolas Daguindau,N. Morineau,Corinne Haioun,Emmanuel Gyan,David Sibon,Remy Gressin,Roch Houot,Gilles Salles,Franck Morschhauser,Guillaume Cartron

Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA.

2020

8053Background: R/R DLBCL treatment remains challenging. Atezolizumab (ATE) and obinutuzumab (OBI) are monoclonal antibodies acting respectively to inhibit T-lymphocyte exhaustion or by inducing ly...

Keywords:

Atezolizumab
Venetoclax
Oncology
B cell
Internal medicine
Obinutuzumab
in patient
Pathology
Refractory
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations